RARE DISEASE
Lambert-Eaton myasthenic syndrome
Lambert-Eaton myasthenic syndrome
Lambert-Eaton myasthenic syndrome
Drug discovery
5
drugs
With orphan designations
Overview
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder targeting presynaptic voltage-gated calcium channels at the neuromuscular junction, impairing acetylcholine release and causing proximal muscle weakness, hyporeflexia, and autonomic dysfunction [1][6][7]. Approximately 50-60% of cases are paraneoplastic, typically associated with small-cell lung cancer (SCLC) [1][6]. Diagnosis involves antibody testing, electromyography, and cancer screening [7][15].
Burden
Health-related quality of life (HRQoL): Significantly lower than in myasthenia gravis and the general population, with impaired physical function (SF-36 score 34.2 vs. 78.6 in genP) [5][9][13].
Diagnostic delays: 58% initially misdiagnosed, often as myasthenia gravis or depression [10][12].
Disability: 25% require wheelchair use; prolonged disease duration in AI-LEMS (median 7.5 years) [10][16].
Therapies
First-line: 3,4-diaminopyridine (amifampridine) to enhance neuromuscular transmission [3][15].
Immunotherapy: IVIG, plasma exchange, or immunosuppressants (e.g., prednisone, azathioprine) for refractory cases [8][14].
Paraneoplastic: Tumor-directed therapy (e.g., chemotherapy for SCLC) improves LEMS outcomes [1][19].
Categories: rare neurological diseases
Research Papers
332 drug discovery papers about Lambert-Eaton myasthenic syndrome, with 1 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
332 drug discovery papers about Lambert-Eaton myasthenic syndrome, with 1 first-in-class and 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-17 | Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular junction disorder characterized by muscle weakness and autonomic dysfunction. While amifampridine is the established first-line symptomatic treatment, longitudinal data regarding the evolution of therapeutic regimens over time and the use of immunosuppressive therapies remain limited. This retrospective study analyzed 70 LEMS patients treated at the Leiden University Medical Center (LUMC) between 1992 and 2023. Treatment was evaluated and a four-point "leg score" was developed and used to retrospectively quantify functional impairment and response to amifampridine. Sixty-six percent of the cohort was female, the median age of diagnosis was 54 years and non-tumor LEMS was more prevalent (77%). All patients used amifampridine at some point, and 91% initiated it within six months of diagnosis. Amifampridine improved leg scores in 57% of patients. Although 58% of patients reported side effects (mostly paresthesia), discontinuation was rare (7%). Pyridostigmine was used in 81% of patients. Immunosuppressive drug use-predominantly prednisolone and azathioprine -increased over time, reaching 44% after five years. Conversely, azathioprine, prednisolone and pyridostigmine were discontinued by 50%, 38% and 32% of patients, respectively, often due to adverse effects. In conclusion, amifampridine provides significant clinical benefits and remains the cornerstone of LEMS therapy. Immunomodulatory therapies were introduced gradually and their use increased over time. Compared with autoimmune myasthenia gravis, immunomodulatory therapy was used less frequently during the early disease course of LEMS.
2026-07-16 | Clinical approach to neurological paraneoplastic syndromes.
Neurological paraneoplastic syndromes are immune-mediated disorders. The diagnosis of paraneoplastic syndromes is often difficult because they are rare and the onset of symptoms usually precedes detection of the underlying malignancy. Accurate diagnosis depends on recognition of the clinical phenotypes likely to be associated with a paraneoplastic aetiology and detection of an anti-neuronal antibody. Clinical phenotypes associated with a high risk of a paraneoplastic cause are limbic encephalitis, encephalomyelitis, rapidly progressive cerebellar syndrome, opsoclonus-myoclonus syndrome, subacute sensory neuronopathy, enteric neuropathy and Lambert Eaton myasthenic syndrome. Clinical phenotypes with an intermediate risk of a paraneoplastic aetiology are brainstem encephalitis, myelopathy, stiff person syndrome, Morvan syndrome and retinopathy. Anti-neuronal antibodies are extremely useful in the diagnosis of paraneoplastic neurological syndromes, but false-negative results can occur when only serum or cerebrospinal fluid (CSF) is tested. Commercial antibody panels do not include all antibodies associated with paraneoplastic syndromes, and if this diagnosis is strongly suspected, serum and CSF should be sent to a research laboratory. The risk of a false-positive result is increased if antibody tests are requested when there is a low pre-test probability of a paraneoplastic syndrome or if an antibody is detected in low titre.
2026-07-01 | Physiotherapy Management of an Older Adult with LambertEaton Myasthenic Syndrome Presenting with Proximal Limb Weakness and Autonomic Dysfunction: A Case Report
Introduction: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune presynaptic disorder of the neuromuscular junction, with an estimated prevalence of approximately 2.6 to 10 cases per million population.1,2 It is frequently under-recognized in physiotherapy settings because its insidious, fatigable proximal weakness can mimic deconditioning, lumbar radiculopathy, or age-related sarcopenia in older adults. This report describes the physiotherapy assessment and rehabilitation of a 60-year-old retired male with autoimmune LEMS, with particular attention to the use of low-intensity, fatigue-monitored exercise progression — an approach with limited prior documentation in the physiotherapy literature, as no controlled trials of physiotherapy specifically in LEMS currently exist. Case presentation: A 60-year-old retired male presented with a six-month history of progressive bilateral proximal lower limb weakness, difficulty rising from a chair and climbing stairs, dry mouth, and mild ptosis that worsened through the day and partially recovered with brief exertion. Tendon reflexes were diminished but augmented following sustained contraction. Management and outcomes: Diagnosis was confirmed by repetitive nerve stimulation showing post-tetanic facilitation and positive P/Q-type voltage-gated calcium channel (VGCC) antibodies, with no malignancy detected on staging investigations. Medical management with pyridostigmine and graded immunotherapy was combined with a physiotherapy programme emphasising submaximal aerobic and resistance exercise, energy conservation education, balance retraining, and fatigue self-monitoring. Over 12 weeks, the patient demonstrated improved manual muscle testing grades, a clinically meaningful reduction in Timed Up and Go time, and improved scores on the Myasthenia Gravis Quality of Life scale, without provoking overwork weakness. Conclusion: Individually tailored, fatigue-monitored physiotherapy can be safely incorporated alongside immunomodulatory and symptomatic pharmacological treatment in LEMS, supporting functional independence in an older adult. Close collaboration between neurology and physiotherapy, with vigilance for overwork weakness and underlying malignancy, is essential.
2026-05-20 | Nanotechnology-driven therapeutic strategies for lambert–eaton myasthenic syndrome: Emerging drug delivery and immunomodulatory approaches
Lambert–Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by impaired acetylcholine release due to autoantibody-mediated targeting of presynaptic P/Q-type voltage-gated calcium channels. Although symptomatic therapies such as amifampridine and immunomodulatory agents provide clinical benefit, their efficacy is limited by short half-life, fluctuating plasma concentrations, systemic toxicity, and dose-dependent adverse effects, including seizures. These limitations highlight the need for advanced drug delivery systems. Recent advances in nanotechnology offer promising strategies to enhance therapeutic precision, bioavailability, and safety in LEMS management. Nanoparticle-based platforms including polymeric nanoparticles and lipid-based nanocarriers enable controlled drug release and improved pharmacokinetic stability, which may help maintain sustained plasma concentrations and thereby enhance drug availability at the neuromuscular junction. In addition, nanocarriers may facilitate improved transport across physiological barriers such as the Blood Nerve Barrier, potentially increasing drug accumulation at presynaptic terminals. Intranasal nanoformulations are explored as a non-invasive systemic delivery strategy, leveraging the highly vascularized nasal mucosa to enhance drug absorption and bypass hepatic first-pass metabolism, thereby improving systemic exposure rather than enabling direct central nervous system targeting. Furthermore, nano-enabled immunomodulation may allow selective suppression of pathogenic autoantibodies while minimizing systemic immunosuppression. This review provides a comprehensive overview of LEMS pathophysiology and current therapies, with a focused discussion on nanotechnology-driven approaches that may overcome existing pharmacological limitations. Future perspectives in targeted delivery, nano-immunotherapy, and biomarker-guided treatment strategies are also highlighted.
2026-04-29 | Lambert-Eaton Myasthenic Syndrome During Immunotherapy in Extensive-Stage Small-Cell Lung Cancer: A Case Report.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction that is frequently associated with small-cell lung cancer (SCLC). It is characterized by proximal muscle weakness, reduced deep tendon reflexes, and autonomic symptoms, all of which can significantly impair quality of life and complicate oncologic management. Early recognition and timely intervention are crucial to improving clinical outcomes. We report a case of a 76-year-old man with extensive-stage SCLC and chronic renal insufficiency whose LEMS worsened during durvalumab immunotherapy. Despite continued chemotherapy and immunotherapy, his symptoms progressively worsened. Chemotherapy failed to improve his neurological condition, with subsequent recurrent episodes of muscle weakness. Subsequent administration of intravenous immunoglobulin (IVIG) combined with pyridostigmine led to marked neurological improvement and restoration of muscle strength to grade 5, enabling continuation of antitumor therapy. The patient subsequently received three cycles of second-line lurbinectedin chemotherapy, during which inflammatory responses, anemia, and venous thrombosis developed but were effectively managed with supportive treatment. Following chemotherapy and immunotherapy, the patient's limb muscle strength recovered to grade 5, followed by recurrent muscle weakness symptoms. Hematologic and biochemical parameters gradually normalized, and inflammatory markers returned to baseline. At discharge, his clinical condition was stable. This case highlights the importance of early recognition and standardized management of paraneoplastic LEMS in enhancing functional recovery and enabling the safe continuation of antitumor therapy.
2026-08-17 | Longitudinal overview of symptomatic and immunosuppressive drugs in LEMS.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular junction disorder characterized by muscle weakness and autonomic dysfunction. While amifampridine is the established first-line symptomatic treatment, longitudinal data regarding the evolution of therapeutic regimens over time and the use of immunosuppressive therapies remain limited. This retrospective study analyzed 70 LEMS patients treated at the Leiden University Medical Center (LUMC) between 1992 and 2023. Treatment was evaluated and a four-point "leg score" was developed and used to retrospectively quantify functional impairment and response to amifampridine. Sixty-six percent of the cohort was female, the median age of diagnosis was 54 years and non-tumor LEMS was more prevalent (77%). All patients used amifampridine at some point, and 91% initiated it within six months of diagnosis. Amifampridine improved leg scores in 57% of patients. Although 58% of patients reported side effects (mostly paresthesia), discontinuation was rare (7%). Pyridostigmine was used in 81% of patients. Immunosuppressive drug use-predominantly prednisolone and azathioprine -increased over time, reaching 44% after five years. Conversely, azathioprine, prednisolone and pyridostigmine were discontinued by 50%, 38% and 32% of patients, respectively, often due to adverse effects. In conclusion, amifampridine provides significant clinical benefits and remains the cornerstone of LEMS therapy. Immunomodulatory therapies were introduced gradually and their use increased over time. Compared with autoimmune myasthenia gravis, immunomodulatory therapy was used less frequently during the early disease course of LEMS.
2026-07-16 | Clinical approach to neurological paraneoplastic syndromes.
Neurological paraneoplastic syndromes are immune-mediated disorders. The diagnosis of paraneoplastic syndromes is often difficult because they are rare and the onset of symptoms usually precedes detection of the underlying malignancy. Accurate diagnosis depends on recognition of the clinical phenotypes likely to be associated with a paraneoplastic aetiology and detection of an anti-neuronal antibody. Clinical phenotypes associated with a high risk of a paraneoplastic cause are limbic encephalitis, encephalomyelitis, rapidly progressive cerebellar syndrome, opsoclonus-myoclonus syndrome, subacute sensory neuronopathy, enteric neuropathy and Lambert Eaton myasthenic syndrome. Clinical phenotypes with an intermediate risk of a paraneoplastic aetiology are brainstem encephalitis, myelopathy, stiff person syndrome, Morvan syndrome and retinopathy. Anti-neuronal antibodies are extremely useful in the diagnosis of paraneoplastic neurological syndromes, but false-negative results can occur when only serum or cerebrospinal fluid (CSF) is tested. Commercial antibody panels do not include all antibodies associated with paraneoplastic syndromes, and if this diagnosis is strongly suspected, serum and CSF should be sent to a research laboratory. The risk of a false-positive result is increased if antibody tests are requested when there is a low pre-test probability of a paraneoplastic syndrome or if an antibody is detected in low titre.
2026-07-01 | Physiotherapy Management of an Older Adult with LambertEaton Myasthenic Syndrome Presenting with Proximal Limb Weakness and Autonomic Dysfunction: A Case Report
Introduction: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune presynaptic disorder of the neuromuscular junction, with an estimated prevalence of approximately 2.6 to 10 cases per million population.1,2 It is frequently under-recognized in physiotherapy settings because its insidious, fatigable proximal weakness can mimic deconditioning, lumbar radiculopathy, or age-related sarcopenia in older adults. This report describes the physiotherapy assessment and rehabilitation of a 60-year-old retired male with autoimmune LEMS, with particular attention to the use of low-intensity, fatigue-monitored exercise progression — an approach with limited prior documentation in the physiotherapy literature, as no controlled trials of physiotherapy specifically in LEMS currently exist. Case presentation: A 60-year-old retired male presented with a six-month history of progressive bilateral proximal lower limb weakness, difficulty rising from a chair and climbing stairs, dry mouth, and mild ptosis that worsened through the day and partially recovered with brief exertion. Tendon reflexes were diminished but augmented following sustained contraction. Management and outcomes: Diagnosis was confirmed by repetitive nerve stimulation showing post-tetanic facilitation and positive P/Q-type voltage-gated calcium channel (VGCC) antibodies, with no malignancy detected on staging investigations. Medical management with pyridostigmine and graded immunotherapy was combined with a physiotherapy programme emphasising submaximal aerobic and resistance exercise, energy conservation education, balance retraining, and fatigue self-monitoring. Over 12 weeks, the patient demonstrated improved manual muscle testing grades, a clinically meaningful reduction in Timed Up and Go time, and improved scores on the Myasthenia Gravis Quality of Life scale, without provoking overwork weakness. Conclusion: Individually tailored, fatigue-monitored physiotherapy can be safely incorporated alongside immunomodulatory and symptomatic pharmacological treatment in LEMS, supporting functional independence in an older adult. Close collaboration between neurology and physiotherapy, with vigilance for overwork weakness and underlying malignancy, is essential.
2026-05-20 | Nanotechnology-driven therapeutic strategies for lambert–eaton myasthenic syndrome: Emerging drug delivery and immunomodulatory approaches
Lambert–Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by impaired acetylcholine release due to autoantibody-mediated targeting of presynaptic P/Q-type voltage-gated calcium channels. Although symptomatic therapies such as amifampridine and immunomodulatory agents provide clinical benefit, their efficacy is limited by short half-life, fluctuating plasma concentrations, systemic toxicity, and dose-dependent adverse effects, including seizures. These limitations highlight the need for advanced drug delivery systems. Recent advances in nanotechnology offer promising strategies to enhance therapeutic precision, bioavailability, and safety in LEMS management. Nanoparticle-based platforms including polymeric nanoparticles and lipid-based nanocarriers enable controlled drug release and improved pharmacokinetic stability, which may help maintain sustained plasma concentrations and thereby enhance drug availability at the neuromuscular junction. In addition, nanocarriers may facilitate improved transport across physiological barriers such as the Blood Nerve Barrier, potentially increasing drug accumulation at presynaptic terminals. Intranasal nanoformulations are explored as a non-invasive systemic delivery strategy, leveraging the highly vascularized nasal mucosa to enhance drug absorption and bypass hepatic first-pass metabolism, thereby improving systemic exposure rather than enabling direct central nervous system targeting. Furthermore, nano-enabled immunomodulation may allow selective suppression of pathogenic autoantibodies while minimizing systemic immunosuppression. This review provides a comprehensive overview of LEMS pathophysiology and current therapies, with a focused discussion on nanotechnology-driven approaches that may overcome existing pharmacological limitations. Future perspectives in targeted delivery, nano-immunotherapy, and biomarker-guided treatment strategies are also highlighted.
2026-04-29 | Lambert-Eaton Myasthenic Syndrome During Immunotherapy in Extensive-Stage Small-Cell Lung Cancer: A Case Report.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction that is frequently associated with small-cell lung cancer (SCLC). It is characterized by proximal muscle weakness, reduced deep tendon reflexes, and autonomic symptoms, all of which can significantly impair quality of life and complicate oncologic management. Early recognition and timely intervention are crucial to improving clinical outcomes. We report a case of a 76-year-old man with extensive-stage SCLC and chronic renal insufficiency whose LEMS worsened during durvalumab immunotherapy. Despite continued chemotherapy and immunotherapy, his symptoms progressively worsened. Chemotherapy failed to improve his neurological condition, with subsequent recurrent episodes of muscle weakness. Subsequent administration of intravenous immunoglobulin (IVIG) combined with pyridostigmine led to marked neurological improvement and restoration of muscle strength to grade 5, enabling continuation of antitumor therapy. The patient subsequently received three cycles of second-line lurbinectedin chemotherapy, during which inflammatory responses, anemia, and venous thrombosis developed but were effectively managed with supportive treatment. Following chemotherapy and immunotherapy, the patient's limb muscle strength recovered to grade 5, followed by recurrent muscle weakness symptoms. Hematologic and biochemical parameters gradually normalized, and inflammatory markers returned to baseline. At discharge, his clinical condition was stable. This case highlights the importance of early recognition and standardized management of paraneoplastic LEMS in enhancing functional recovery and enabling the safe continuation of antitumor therapy.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
5 orphan drug designations for Lambert-Eaton myasthenic syndrome, including 1 approved therapy.
5 orphan drug designations for Lambert-Eaton myasthenic syndrome, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
3,4 diaminopyridine and choline bitartrate | small molecules | FDA | 2010-04-30 | — | MS Therapeutics Limited |
amifampridine [Firdapse] | small molecules | FDA | 2009-11-12 | 2022-09-29 | Catalyst Pharmaceuticals, Inc. |
Amifampridine phosphate [Firdapse] | small molecules | EMA | 2002-12-18 | — | Biomarin International Limited |
amifampridine | small molecules | FDA | 1990-12-18 | — | Catalyst Pharmaceuticals, Inc. |
Dynamine | small molecules | FDA | 1990-02-05 | — | Mayo Foundation |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.